Randomized Trialhigh evidence
Association of testosterone-induced increase in neutrophil and monocyte counts with thromboembolic events: The TRAVERSE trial.
American heart journal·October 1, 2025·PMID 40246046
Why it mattersThis analysis identifies a potential mechanism linking testosterone therapy to thromboembolic risk through leukocyte changes, offering a biomarker for risk stratification in a population where TRT use is common but cardiovascular safety remains debated.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled